HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Baere, T. Articles by Roche, A. J. Search for Related Content PubMed PubMed Citation Articles by de Baere, T. Articles by Roche, A. J.

Hepatic Intraarterial ¹³¹I Iodized Oil for Treatment of Hepatocellular Carcinoma in Patients with Impeded Portal Venous Flow¹

¹ From the Departments of Interventional Radiology (T.d.B., V.K., A.J.R.), Medicine (M.D.), and Nuclear Medicine (J.L.), Institut Gustave Roussy, 94805 Villejuif, France; the Department of Medical Imaging, Saint Eloi Hospital, Montpellier, France (P.T.); and the Department of Medical Imaging, Hôpital Saint Antoine, Paris, France (J.M.T.). Received May 4, 1998; revision requested July 6; final revision received December 14; accepted March 26, 1999. Address reprint requests to T.d.B.

PURPOSE: To evaluate the efficacy and safety of intraarterial hepatic iodine 131 iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow.

MATERIALS AND METHODS: Twenty-four patients (mean age, 61 years) with hepatocellular carcinoma underwent 38 courses of ¹³¹I iodized oil (one to three per patient), with a mean dose of 2,146 MBq injected into the proper hepatic artery. Hepatocellular carcinoma manifested as single nodules (n = 8; mean, 7.75 cm), multiple nodules (n = 13; mean, 5.46 cm), or a mass (n = 3) occupying more than two hepatic segments. Portal venous thrombosis was complete (n = 10), right (n = 9), left (n = 2), or multisegmental (n = 1). Two patients had hepatofugal portal flow.

RESULTS: Among the 23 patients with evaluatable results, response to treatment was partial in three, and disease was stable in 12 and progressive in eight. Estimated actuarial survival rates were 70%, 33%, 12%, and 6% at 3, 6, 9, and 12 months, respectively, with two patients alive at 9 and 11 months. The median survival time was 147 days. Adverse events were the early death of one patient owing to hepatic failure and transient symptomatic hepatic failure after 12 courses in nine patients.

CONCLUSION: In this preliminary experience, intraarterial hepatic ¹³¹I iodized oil did not demonstrate high efficacy in the treatment of hepatocellular carcinoma in patients with portal venous thrombosis, as side effects were not rare.

Index terms: Hepatic arteries, therapeutic blockade, 952.1266 • Iodine and iodine compounds, radioactive, 761.1266 • Liver neoplasms, chemotherapeutic infusion, 761.1266, 761.323 • Portal vein, stenosis or obstruction, 957.751 • Radionuclides, therapeutic, 761.1266, 761.323 • Therapeutic radiology, 761.1266, 761.323

This article has been cited by other articles:

				W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]

				B. Lambert, K. Bacher, K. De Keukeleire, P. Smeets, I. Colle, J. M. Jeong, H. Thierens, R. Troisi, F. De Vos, and C. Van de Wiele 188Re-HDD/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis J. Nucl. Med., August 1, 2005; 46(8): 1326 - 1332. [Abstract] [Full Text] [PDF]